Phase 2b Trial of Pirepemat, to Prevent Falls, Approved in Sweden
IRLABÂ has received approval from the Swedish Medical Products Agency (MPA) to conduct a Phase 2b trial for its investigational…
Articles by Yedida Y Bogachkov PhD
Parkinson’s UK Funds Work Into Inflammation That May Drive Disease
Parkinson’s UK is investing up to £3 million (about $3.96 million) over the next two-and-a-half years to support research into…
Apomorphine Infusion Device Again Before FDA for Approval
Supernus Pharmaceuticals has again applied to the U.S. Food and Drug Administration (FDA) requesting that its apomorphine infusion device…
Study: Parkinson’s Patients Speak 60% Less Than Healthy Peers
People with Parkinson’s disease verbally communicate less than those without the neurodegenerative disorder, according to a recent study that…
UCB and Novartis Join to Advance Oral Therapy Now in Phase 2 Trial
UCB is partnering with Novartis to co-develop and potentially market UCB0599, a small molecule to inhibit misfolding of the…
Swedish Researchers Develop Tools to Manage Care More Effectively
A Swedish group of doctors and researchers are working to develop new tools and models to more effectively manage and…
Wearable, AI-assisted UltiGesture May Curb Gait Freezing
An interdisciplinary research team from William and Mary University and Virginia Commonwealth University (VCU) are working on artificial intelligence programming…
Parkinson’s Foundation Opens 2022 Community Grant Applications
Applications are open for the Parkinson’s Foundation 2022 community grant cycle, with $1 million to be awarded to help…
Gut Microbiome of Patients Found to Contain Unique Bacterial Profile
Researchers at the biotech company Second Genome have identified specific intestinal bacterial strains that are either enriched or depleted…
Phase 1b Trial of YTX-7739 Shows Safety, Early Potential in Patients
Yumanity Therapeutics announced that its investigational therapy, YTX-7739, worked to safely inhibit stearoyl-CoA desaturase — an enzyme thought to…